We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Accepts Mitsubishi NDA for ALS Treatment
The FDA has accepted the NDA for Mitsubishi’s edaravone drug, putting it on course to be the first approved treatment for amyotrophic lateral sclerosis (ALS) in more than 20 years.